Review article
https://doi.org/10.20471/LO.2020.48.02-03.14
First-line treatment of advanced ovarian cancer: an expert update
Branka Petrić-Miše
; Department of Oncology, University Hospital Split and School of Medicine Split, Croatia
Abstract
Ovarian cancer is the fifth most common cause of death among malignant diseases in women in Europe. The standard treatment is cytoreductive surgery, followed by platinum-taxane based chemotherapy. In patients with advanced disease, a valid option is a neoadjuvant chemotherapy followed by interval debulking surgery. Despite the progress in primary treatment, almost 70% of the patients relapse. There is a significant need for better first-line treatment to avoid or delay relapse and improve ovarian cancer outcomes. The most significant change involves the changes in the treatment schedule and new drugs in first-line chemotherapy. Bevacizumab is approved in first-line treatment combined with carboplatin and paclitaxel as it improves progression-free survival (PFS) in patients with a higher risk of recurrence. After achieving the response to first-line chemotherapy, maintenance therapy with poly-adenosine-diphosphate-ribose-polymerase (PARP) inhibitors prolongs PFS in patients with homologous recombination deficiency (HRD). Patients with BRCA mutations obtain the most significant benefit.
Keywords
ovarian cancer; chemotherapy; Bevacizumab; PARP inhibitors
Hrčak ID:
250349
URI
Publication date:
21.12.2020.
Visits: 1.313 *